Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:KOD NASDAQ:PHVS NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.48+0.1%$15.79$7.28▼$16.88$2.12B1.411.16 million shs1.17 million shsKODKodiak Sciences$36.14$38.72$3.43▼$47.84$2.26B2.21684,070 shs1.21 million shsPHVSPharvaris$32.80$30.02$16.72▼$34.41$2.15B-2.35307,426 shs182,167 shsSAGESage Therapeutics$8.68$8.88$6.35▼$9.36$543.54M0.262.32 million shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+4.17%+6.66%+17.54%+108.07%KODKodiak Sciences0.00%+6.11%-3.39%+62.28%+923.80%PHVSPharvaris0.00%+6.77%+7.40%+26.15%+97.12%SAGESage Therapeutics0.00%0.00%0.00%0.00%-4.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.48+0.1%$15.79$7.28▼$16.88$2.12B1.411.16 million shs1.17 million shsKODKodiak Sciences$36.14$38.72$3.43▼$47.84$2.26B2.21684,070 shs1.21 million shsPHVSPharvaris$32.80$30.02$16.72▼$34.41$2.15B-2.35307,426 shs182,167 shsSAGESage Therapeutics$8.68$8.88$6.35▼$9.36$543.54M0.262.32 million shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+4.17%+6.66%+17.54%+108.07%KODKodiak Sciences0.00%+6.11%-3.39%+62.28%+923.80%PHVSPharvaris0.00%+6.77%+7.40%+26.15%+97.12%SAGESage Therapeutics0.00%0.00%0.00%0.00%-4.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.33Hold$17.254.68% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1416.61% UpsidePHVSPharvaris 2.69Moderate Buy$49.1849.94% UpsideSAGESage Therapeutics 2.00Hold$9.205.99% UpsideCurrent Analyst Ratings BreakdownLatest SAGE, AUPH, KOD, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026PHVSPharvaris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.005/1/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/21/2026PHVSPharvaris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PHVSPharvaris CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/9/2026PHVSPharvaris Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$42.004/8/2026PHVSPharvaris Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$42.004/7/2026PHVSPharvaris WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$41.00 ➝ $42.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$283.05M7.49$1.01 per share16.24$4.41 per share3.74KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/APHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/ASAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.177.5920.60N/A99.97%26.62%19.65%7/30/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%N/ALatest SAGE, AUPH, KOD, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.085.555.01KODKodiak SciencesN/A3.543.54PHVSPharvarisN/A11.2411.24SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%KODKodiak Sciences89.06%PHVSPharvarisN/ASAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%KODKodiak Sciences45.90%PHVSPharvaris11.84%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300128.60 million112.91 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSAGE, AUPH, KOD, and PHVS HeadlinesRecent News About These CompaniesSage Potash Secures All Permits for its Drilling Program at Sage Plain Potash Project in UtahJune 18 at 9:00 AM | newsfilecorp.comNFormer Sage Therapeutics executives launch neurology biotech with $106MApril 21, 2026 | bizjournals.comTortugas comes out of shell with $106M, 4 ph. 2-stage neuro medsApril 21, 2026 | fiercebiotech.comFTortugas debuts with $106M and brain drugs from Hansoh, EisaiApril 21, 2026 | finance.yahoo.comBoston Man to Settle SEC Insider Trading Case Over Drug DenialJanuary 28, 2026 | news.bloomberglaw.comNSupernus a new buy at BofA on 'underappreciated' CNS assetsOctober 29, 2025 | seekingalpha.comBiogen’s Zurzuvae approved as first postpartum depression drug in EuropeSeptember 18, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026The Market May Be Missing What’s Changing at BigBear AIBy Thomas Hughes | June 8, 2026GitLab’s Price Recovery Gains Traction—Time to Get On Board?By Thomas Hughes | June 4, 2026NVIDIA Sends a Message With RTX Spark—This Is What It SaysBy Thomas Hughes | June 5, 20263 Non-Pharma Firms That Could Benefit From the GLP-1 TrendBy Nathan Reiff | June 20, 2026SAGE, AUPH, KOD, and PHVS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$16.48 +0.02 (+0.12%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$16.47 -0.01 (-0.05%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Kodiak Sciences NASDAQ:KOD$36.14 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$35.49 -0.65 (-1.80%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Pharvaris NASDAQ:PHVS$32.80 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$32.73 -0.07 (-0.21%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Sage Therapeutics NASDAQ:SAGESage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
